Gain Therapeutics develops small molecule drugs for neurological and rare genetic diseases, based in Bethesda, Maryland. GANX reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 31 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 12 | BTIG | Reiterated | Buy | |
| Jul 1 | HC Wainwright & Co. | Reiterated | Buy | |
| Jun 30 | BTIG | Maintained | Buy |
Seasonality
How GANX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in GANX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GANX is in one of them and how their past GANX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GANX in an article yet. Here's the latest on the wider market.
About Gain Therapeutics
Gain Therapeutics is a biotechnology company in Bethesda, Maryland, that develops small molecule drugs for diseases caused by misfolded proteins. Its lead candidate, GT-02287, is being tested for Parkinson's disease. The company is also working on treatments for lysosomal storage disorders, metabolic disorders and oncology. It uses its Magellan computational platform to find sites on disease-linked proteins where drugs can bind and to design molecules that fit those sites.
- Headquarters
- Bethesda, MD